Caas Capital Management LP Spruce Biosciences, Inc. Transaction History

Caas Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.33 - $5.74 $64,182 - $158,114	-27,546 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.01 - $11.26 $389,844 - $730,391	-64,866 Reduced 70.19%	27,546 $166,000
Q2 2021 Aug 16, 2021	BUY	$10.12 - $17.46 $935,209 - $1.61 Million	92,412 New	92,412 $1.04 Million
Q1 2021 May 17, 2021	SELL	$14.8 - $25.79 $148,000 - $257,900	-10,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$15.38 - $32.42 $153,800 - $324,200	10,000 New	10,000 $243,000

15.4M

16.7K

1.1K

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $9.42M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.